The aim of this report is to assess the added benefit of dimethyl fumarate (DMF) in comparison with the appropriate comparator therapy (ACT) in adult patients with relapsing remitting multiple sclerosis (RRMS).
http://ift.tt/2ssnHro
Τετάρτη 14 Ιουνίου 2017
Dimethyl Fumarate -- Benefit Assessment According to §35a Social Code Book V [Internet].
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Abstract The changes of dissolved organic matter (DOM) components during stabilization process play significant effects on its redox prope...
-
Publication date: September 2017 Source: European Journal of Surgical Oncology (EJSO), Volume 43, Issue 9 http://ift.tt/2gezJ2D
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου